Mr Forster has close to 20 years industry experience in biotechnology and pharmaceutical companies.

Prior joining Solace, Mr Forster was head of EU development and of development Operations in the EU & Asia at Pfizer. During his career at Pfizer he was integral to bringing a number of drugs to market, including Celebrex, Bextra and Relpax.

George Horner III, chairman of Creabilis, said: “We are delighted that Eliot has joined Creabilis. His proven drug development experience will be extremely valuable as we work to further advance of our exciting pipeline of clinical drug candidates.

“Eliot's appointment is another important step in Creabilis bringing highly innovative treatments for skin diseases to market.”

Mr Forster said: “Creabilis has the potential to make a significant difference to the way serious skin diseases are treated. Our lead product, CT327, is advancing through the clinic and highlights the potential of our Low Systemic Exposure technology to deliver innovative new chemical entities, targeting significant unmet medical needs.

“I very much look forward to working with the exceptional team at Creabilis and delivering on the undoubted promise of the Company's pipeline and underlying science.”

Will Mr Forster’s experience benefit the firm?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.